
Benzinga Pro data, Enanta Pharmaceuticals (NASDAQ:ENTA) reported Q2 sales of $18.72 million. Earnings fell to a loss of $33.59 million, resulting in a 11.55% decrease from last quarter. Enanta Pharmaceuticals collected $27.65 million in revenue during Q1, but reported earnings showed a $30.11 million loss.